The detection methods for existing well-established biomarkers, including β-amyloid (Aβ), phosphorylated-tau (P-tau), and total tau (T-tau) in cerebrospinal fluid (CSF), and techniques such as structural magnetic resonance imaging (MRI) and positron emission tomography imaging for AD are invasive, expensive, inconvenient, and difficult to implement under resource-limited settings [2]. The gene discussed is MAPT; the disease is Alzheimer disease.